1st Circ. Won't Rethink Ending Sarepta Securities Suit
The First Circuit refused Wednesday to reconsider its August decision upholding the dismissal of a putative securities class action accusing drugmaker Sarepta Therapeutics Inc. of misleading investors over the possibility of...To view the full article, register now.
Already a subscriber? Click here to view full article